Studies a gene variant in people with psoriasis and psoriatic arthritis treated with methotrexate
Studies a gene variant in adults with psoriasis or psoriatic arthritis who take methotrexate.
Key facts
- Who runs it
- South Valley University
- Where
- Qina, EgyptSee the site
- Trial code
- Registry title
- Genetic Variation in TRAF3IP2 (rs13190932)
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 1 Jun 2025
- Planned end
- 10 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methotrexate
- Record updated
- 25 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with psoriasis or psoriatic arthritis of moderate or severe skin severity. People starting methotrexate join the follow-up part.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Psoriasis vulgaris or psoriatic arthritis confirmed by a dermatologist or rheumatologist. Skin severity by PASI score: 7-12 (moderate) or above 12 (severe).
- Earlier treatment
- People currently on immunosuppressive or systemic therapies cannot join. For the follow-up part, people must be starting methotrexate.
- Biomarker or test result
- People who already had genetic analysis for the TRAF3IP2 gene change (rs13190932) cannot join.
Main reasons for not taking part
- Other autoimmune conditions, such as rheumatoid arthritis or lupus
- Pregnancy or breastfeeding
- Current immunosuppressive or systemic therapy
- Liver or kidney impairment
- Active or uncontrolled infection, including tuberculosis
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients aged 18 -70years
- the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist
- Willingness to participate: Signed informed consent
- Initiating methotrexate (MTX) therapy: For prospective cohort
- Availability for follow-up: Patients must be willing and able to attend scheduled visit
Who cannot take part
- Patients currently undergoing immunosuppressive or systemic therapies
- Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932)
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- Patients with known genetic disorders affect immune system function
- Patients with liver or kidney impairment
- Patients with allergy or contraindication to methotrexate
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis
- Pregnancy and lactation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in Egypt
- Qena HospitalQina, EgyptContact: Mohamed Hosny Hassan, ProfessorTaking people
About the trial
What the trial wants to find out
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.
Read full original descriptionShow less
It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.
The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.
The 3 groups in the trial
- Group AExisting treatment, for comparison
About 30 patients suffering from psoriasis
Treatment: Methotrexate
- Group BExisting treatment, for comparison
About 10 patients suffering from psoriatic arthritis
Treatment: Methotrexate
- Group CTreatment being tested
About 10 healthy control group
Treatment: Methotrexate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate
- Plain-language title
- Studies a gene variant in people with psoriasis and psoriatic arthritis treated with methotrexateGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07086924, who can take part
- Record updated
- 25 July 2025